A Randomized, Double Blind, Placebo Controlled, Parallel Group, Phase 3 Study of MAP0004 in Adult Migraineurs for a Single Migraine Followed by Open Label Extension.

Trial Profile

A Randomized, Double Blind, Placebo Controlled, Parallel Group, Phase 3 Study of MAP0004 in Adult Migraineurs for a Single Migraine Followed by Open Label Extension.

Completed
Phase of Trial: Phase III

Latest Information Update: 21 Jul 2014

At a glance

  • Drugs Dihydroergotamine mesilate (Primary)
  • Indications Migraine
  • Focus Registrational; Therapeutic Use
  • Acronyms FREEDOM-301
  • Sponsors MAP Pharmaceuticals
  • Most Recent Events

    • 02 Aug 2011 Results from the primary part of the trial and the long-term safety extension were used as the basis of a NDA, which has been submitted to the US FDA.
    • 07 Apr 2011 Full results of the study were published in the journal Headache, according to a MAP Pharmaceuticals media release.
    • 01 Apr 2011 Results published in the Headache.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top